Chinese Journal of Pharmacoepidemiology is an academic journal in the field of pharmacy and pharmacoepidemiology, which is directed by Hubei Provincial Drug Administration and jointly sponsored by Hubei Institute for Drug Control, Chinese Pharmaceutical Association and Zhongnan Hospital of Wuhan University. The journal focuses on reporting the latest research results and methods related to pharmacology and pharmacoepidemiology. It is indexed as the Core Journal in Chinese science and technology field, and as a statistical source journal of Chinese scientific and technical papers. The journal has been included by International Pharmaceutical Abstracts, American Chemical Abstracts (CA), WHO Western Pacific Region Index Medicus and other famous international retrieval organizations. The journal is published monthly on the 15th of each month, large 16 format, ISSN 1005-0698, CN 42-1333/R, postal distribution code 38-187. The official website is ywlxbx.whuznhmedj.com.

1 Columns

The main columns of the journal include: commentaries, expert perspective, reviews, articles (primary research, secondary research, methodological research), guidelines and consensus, practice and communication (case reports, case studies), etc. Comments, expert ideas and reviews are invited contributions. In principle, freelance manuscripts are not accepted; for freelance reviews, please contact our editorial office first and wait for the editorial office to evaluate before making a formal submission. For guidelines and consensus, it is recommended to contact our journal at the beginning of their development so that they can be published quickly after they are completed.

Our journal also offers occasional columns focusing on the latest research spotlights in pharmacoepidemiology, and we welcome interested experts and scholars to contact our editorial office.

2 Submission requirements

2.1 Manuscripts

The manuscript should be scientific, innovative and practical, with clear arguments, true information, reliable data, concise text, clear hierarchy, prominent focus and accurate conclusions. The format and content of the manuscript should follow the report specifications for different types of medical research (for details see the attached table), and the electronic version of the manuscript should be in WORD file format.

The structure of the articles should be in the following order: title, author and affiliation, abstract and keywords in Chinese and English, introduction, object (data) and methods, results, discussion, acknowledgement, and references in body. The hierarchical system of the manuscript should be marked with 1, 1.1, 1.1.1 ......, etc. and written in top frame. After the hierarchical coding, the title should be formulated.

2.2 Title

The title should be concise and accurate, which can summarize the themes of the article. The Chinese title should generally not exceed 28 words, without a subtitle, and should be accompanied by an English title. Abbreviations, characters, codes, etc. should not be used in the title as far as possible.

2.3 Author and affiliation

The author names should be listed under the Chinese title. The order of the author names should be determined at the time of submission, and cannot be changed in the process of manuscript layout and revision. If the authors belong to different units, institutions, institutes, or departments, they should add serial numbers 1, 2, 3, etc. in the upper right corner of their names, and then the name, address, postal code, and country name of each affiliation should be listed in detail under the affiliations, along with the corresponding English information of the affiliations.

The undersigned author should have all four of the following: ① make significant contributions to the idea or design of the study, or participate in the acquisition, analysis or interpretation of data in the study; ② draft the research paper or revise important content; ③finalize the version to be published; ④ agree to take responsibility for all aspects of the research to ensure that doubts related to the accuracy or integrity of any part of the paper are properly investigated and resolved. Those who do not meet all four criteria should be acknowledged at the end of the text. Those who only participate in obtaining funding or in the general management of the research group should also not be listed as authors. At least one author must be responsible for each of the main conclusions of the paper. Collectively signed articles must identify the primary responsible person for the article, and other contributors to the research may be included in the acknowledgments. If any of the authors are foreign, their consent should be obtained with a letter of certification.

Author's responsibility: The contribution of each author must be indicated when submitting the manuscript. Authors should provide the most convenient contact information: phone number, email address, mailing address, etc. If there is more than one author, the corresponding author should be designated and informed of his/her academic degree, title, whether he/she is a Master/PhD supervisor and email address. Authors should actively cooperate with the editorial office to review and publish the manuscript.

2.4 Abstract

Please attach an abstract in Chinese and English, Chinese abstract is limited to 500 words, and the English abstract should basically correspond to the Chinese abstract, or it can be more detailed than the Chinese abstract. The article requires a structural abstract, including objective, methods, results and conclusion. Review  and case reports require narrative abstracts, which should be written in the third person, without subjects such as "this article" and "author". Unless necessary, the abstract should not contain diagrams, tables, chemical structural formulas, symbols and terms that are not commonly known and used.

2.5 Key words

Please list 3-8 terms that reflect the characteristic content of the paper and have strong generality as keywords, and try to use the words listed in the Medical Subject Headings (MeSH) in the latest Index Medicus. It is not appropriate to use English words or abbreviations for Chinese keywords, and the first word of English keywords should be capitalized. The keywords should be separated with semicolons.

2.6 Introduction

Summarize the relevant theoretical basis, research ideas, experimental basis and the current situation at home and abroad, and clearly explain the specific purpose, novelty or characteristics of the research.

2.7 Subjects(data) and methods

Scientific research papers must follow the basic principles of medical ethics. When human subjects are reported, it should be stated in the paper whether the procedures followed conform to the ethical standards set by the ethical review committee (unit, region, country) responsible for human trials, whether informed consent was obtained from the subjects or their guardians, and the approval number should be listed in the paper; when the subjects are animals, it should be stated whether the unit and national regulations on the management and use of laboratory animals were followed. If it is approved, the approval number should be recorded in the paper. Please upload the above supporting documents electronically at the time of submission.

The information of study subjects, drugs, reagents and main instruments should be complete. The study methods should be specific, and basis should be provided in the literature when there are references to the methods of others.

2.8 Statistical method

①Statistical symbols should be typed in italics in accordance with the relevant provisions of GB3358.1-2009 "Statistical Vocabulary and Symbols"; ②The use of ± s indicates quantitative information that obeys normal distribution, and M (QR) indicates quantitative information with skewed distribution; when using relative numbers, the denominator should not be less than 20; ③According to the type of design used, the conditions available for the information and the purpose of analysis, select the appropriate statistical methods to analyze the research results; ④ When P < 0.05, it means that the difference between the comparison groups is statistically significant, and should not be described as a significant difference between the comparison groups.

2.9 Figures and tables

Figures and tables should complement, not duplicate the content of the text. Each figure and table should have a concise title in Chinese and English. Tables should be in three-line table format, and auxiliary lines can be added if necessary. The vertical and horizontal headings of the table should be reasonably arranged and the meaning of the data should be clearly expressed; for the data in the table, the same indicator should retain the same number of decimal places, and the descriptive information should be placed in the notes below the chart, and all non-public abbreviations used in the chart should be indicated in the notes. The chart should not be too large, the maximum width of the half-column chart should not exceed 7.5 cm, the full-column chart should not exceed 16.0 cm, the ratio of height to width should be about 5:7. The type of figure should match the nature of the data and make the scale value on the number axis conform to the mathematical principles. Photos require good clarity and contrast. If a portrait is used, written consent should be obtained from the person, or the part of the portrait that can be identified as the person should be covered. Photographs of gross specimen should have scale markings within the figure, and pathology photographs should indicate the method of staining and magnification. All figures should be submitted as original files in 300dpi tiff or PDF format and uploaded in order when submitting the manuscript.

2.10 Chinese name of the drug

Tale the "Pharmacopoeia of the People's Republic of China (2020 Edition)" and the "Chinese Drug Generic Names" 1997 edition and 1998 supplement by Chinese Pharmacopoeia Commission as criteria: new drugs approved by National Medical Products Administration use the approved drug names; foreign drugs use the international non-proprietary names (INN); Chinese herbal medicines should use the proper name, drugs that the pharmacopoeia does not contain should be accompanied by Latin; Chinese patent medicines use generic name. Uncommon Chinese drug names, new drug names and abbreviations of drug names should be indicated in parentheses with the full English name when they first appear in the paper. When the drug name is long and appears frequently in the paper, abbreviation can be used and noted when it first appear, such as mycophenolate mofetil (MMF). Trade names and code names can be indicated in parentheses after the generic name.

2.11 Numbers vs. significant figures

Where it is appropriate to use Arabic numerals for expression, Arabic numerals should be used. Chinese characters should be used in following cases: ① numbers as lexical elements to form stereotyped words, phrases, idioms, abbreviations or expressions with rhetorical overtones such as 一律、十二指肠、三叉神经痛, etc.; ② two adjacent numbers side by side to indicate the probable number, such as 三五天、二三米; ③ the number in front of the adjective, such as 这一实验方法有四大优点; ④ indefinite quantifiers, such as 任何一个人，3 d为一疗程; ⑤ When several parallel Arabic numbers are connected with compound indices, the compound indices should be in Chinese characters, such as 几组数据中都含有3、6、9三个数. The Gregorian century, era, year, month, day, and moment are always in Arabic numerals. The year should be written in full in Arabic numerals, such as 1995, and words that can be easily misunderstood by the passage of time should be avoided, such as "this year" and "last year".

The increase in numbers can be expressed in multiples, and the decrease in numbers can only be expressed in fractions or percentages, such as an increase of 1 times, a decrease of 1/4 or a decrease of 25%. The starting and ending numbers of percentages should be marked out with %, such as 1% to 5%, and can not be written 1 to 5%. Units need to be marked, when there are Volume and area before and after the number, such as 2 cm × 3 cm × 5 cm, and it can not be written 2 × 3 × 5 cm, 4 cm × 5 cm can not be written 4 × 5 cm. If range of parameters have the same units, only one parameter unit should be written, such as 36 ~ 38 ℃, 120 ~ 180 nm, (25.3 ± 0.1) nm.

^{When a series of values are calculated in the same units, the unit symbol is allowed to be written after the last number, e.g. 6.0, 8.0, 12.0 mol-L-1. The experimental data should be treated statistically as necessary. The measured data should not exceed the precision of its measuring instrument, for example, 6 347 means 1/6 000 of the precision. Only the last digit of the number is allowed to have error, the preceding digits should not have error.}

2.12 Units of measurement and symbols

"Legal Units of Measurement of the People's Republic of China" (referred to as "legal units") , which are based on the International System of Units, should be adopted for all units of measurement. Please refer to "Volume and Units" (Standard Press of China). Volume names and volume symbols should be standardized and written.

2.13 Abbreviation

Any publicly recognized abbreviations can be used directly without comments, such as DNA, HBsAg, etc. Abbreviations that are not yet publicly recognized or whose full names are too long, and appear several times in the paper should be written out in full at the first appearance, with the abbreviation or acronym in parentheses. Abbreviations of medical terms are recommended for common methods of medication: oral medication (po), intravenous injection (iv), intravenous drip (ivd), intramuscular injection (im), intraperitoneal injection (ip), subcutaneous injection(sc), once daily (qd), every other day (qod), twice daily (bid), three times daily (tid), four times daily (qid).

2.14 Discussion

It should be based on the results of the paper, combined with the conclusions of the relevant literature retrieved, focusing on the new findings, ideas and conclusions of the paper; The basis and premises of the inference should be stated, including what is not supported (limitations of the test conditions, etc.); Ideas, recommendations, and questions for further research are presented based on the reliability of inferences or conclusions. The content of the discusstion, introduction and results, should have its own bias and should not be repeated.

2.15 Acknowledgements

Acknowledgement can be given to persons or units who have made substantial contributions or assistance in the process of research and writing the paper, but are not yet enough to be listed as the authors of the paper.

2.16 References

The citation of references should follow the principles of reasonableness, correctness and adequacy, avoiding omission and blind citation, and should grasp the relevance of reference citations, keep a good amount and degree, and priority citation of published literature within the last five years are encouraged. In principle, the number of references should not be less than 20.

According to GB7714-2015 "Information and Literature Reference Bibliographic Rules", the bibliographic format adopts the sequential coding system, and the citations in the text are marked with Arabic numerals plus square brackets according to the order in which they appear. Try to avoid citing abstracts as references. When it is necessary to cite a personal communication, the name of the correspondent and the time of the communication can be written in brackets and inserted in the corresponding part of the text. The reference table at the end of the article only needs to list the names of the first three authors. Full names should be used for Chinese author names and journal names, abbreviations of foreign author names and journal names shall follow the format of Index Medicus. References must be checked by the author with their original text.

For example：

Journal articles

Chinese literature needs to be translated into English.

曾宪涛, 蔡广研, 陈香美, 等. 制定/修订《临床路径释义》的基本方法与程序[J]. 中华医学杂志, 2017, 97(40): 3140-3142. [Zeng XT, Cai GY, Chen MX, et al. Basic methods and procedures for formulating/revising the Interpretation of Clinical Pathways[J]. National Medical Journal of China, 2017, 97(40): 3140-3142.] DOI: 10.3760/cma.j.issn.0376-2491.2017.40.004.

English literature

Wang X, Li S, Liu T, et al. Laparoscopic pyelolithotomy compared to percutaneous nephrolithotomy as surgical management for large renal pelvic calculi: a meta-analysis[J]. J Urol, 2013, 190(3): 888-893. DOI: 10.1016/j.juro.2013.02.092.

Group authors

中国研究型医院学会泌尿外科学专业委员会, 中国医疗保健国际交流促进会泌尿健康促进分会, 中国医疗保健国际交流促进会循证医学分会, 等. 中国良性前列腺增生症经尿道等离子双极电切术治疗指南(2018简化版)[J]. 中国循证医学杂志, 2018, 18(6): 543-546. [Chinese Society of Research Hospitals Urological Surgery professional Committee, Urological Health Promotion Branch of China Medical Care International Exchange Promotion Association, China Association for the Promotion of International Exchanges in Healthcare Evidence-based Medicine Branch, et al. Transurethral bipolar plasmakinetic prostatectomy treatment for benign prostatic hyperplasia in Chinese: development of a national evidence-based clinical practice guideline (2018 simplified version), 2018, 18(6):543-546.] DOI: 10.7507/1672-2531.201804068.

Books

Chinese: 郭祖超，主编.医用数据统计方法，第3版[M].北京：人民卫生出版社，1988：259-303.

English: Strom BL.Pharmacoepidemiology[M].New York: Churchill Liningstone,1989： 173-187

Pharmacopoeia

中国药典2010年版. 二部[S]. 2020：50

USP 29[S].2006：1001

Martidale.The Extra Pharmacopoeia.31st ed[S].1996：50

Newspapers

程书权. 中药临床药学研究现状[N].中国医药报，2001-12-13（6）

Patents

姜锡洲.一种温热外敷药制备方案:中国专利,881056073[P].1989-07-26

Dissertation

罗晓健.复方丹参多层缓释片及其体内外评价方法的研究[D].沈阳：沈阳药科大学，2001

Academic conference memoir

余立新. 第三届全国膜和膜过程学术报告会议论文集[C]. 北京：高教出版社，1999： 421-425

Electronic literature

王明亮. 关于中国学术期刊标准化数据库系统工程的进展［EB/OL］.（1998-08-16）[1998-10-04].http://www.cajcd.edu.cn/pub/wml/txt/980810-2.html

ICMJE. Clinical Trials Registration: Which trials registries are acceptable to the ICMJE?[EB/OL]. (2007-07-10) [2020-12-12]. http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/

2.17 Funded manuscripts

Manuscripts that have received funding will be given priority for publication once they are accepted. If the subject of the manuscript is a funded project, it should be annotated on the left bottom of the title page and a copy of the fund certificate should be attached; For items without a code, please replace the item code with the code of the document.

For example：

Funding: 国家重点研发计划（2016YFC0106300）；国家社会科学基金青年项目（14CXW036）；国家自然科学基金青年项目（81603496）。

2.18 Research Registration

Randomized controlled trials are required to provide the registration number and URL on a WHO-accredited Level 1 registration platform or Clinicaltiral.gov (https://clinicaltrials.gov/).

For details, see:

邬兰, 田国祥, 王行环, 等. 临床试验的注册及注册平台比较分析[J]. 中国循证心血管医学杂志, 2017, 9(2): 129-134. DOI:10.3969/j.issn.1674-4055.2017.02.01.

3 Submissions

3.1 Contributions

The journal only accepts submissions from the online submission system，please go to our website “ywlxbx.whuznhmedj.com”, submit your manuscripts through the "User Login Area" screen. After submitting the manuscript, authors can keep track of what the editorial board is doing with the manuscript through the online submission system.

Our journal is exempt from reviewing fees, and once the manuscript is accepted, it will be charged according to the relevant standards and invoiced accordingly.

3.2 Cautions

①The authors should declare that the manuscript is free from infringement, double submission, confidentiality, and signature dispute.

②The authors must be responsible for the authenticity of the article. If any falsification of the article is found, the published article of the author will be cancelled and the author will be informed of the falsification in the journal and peer journals, and the author will be disqualified from publishing any article in the journal for 2 years.

③The authors must keep the original materials of the study before submitting, i.e., the data tables included in the analysis, the source files of the statistical analysis software (e.g., files with the suffix ".rm5" for the RevMan 5 software). After submission, the original data materials (electronic and/or print copies) should be submitted to the editorial office for review and inspection.

④The authors must carefully review the figures and tables and their data in the submitted manuscript before submission, and make sure that the figures and data are exactly as described in the text.

⑤According to the relevant provisions of Copyright Law, the editorial office has the right to delete and revise the manuscript. If the author of the accepted manuscript has different opinions on the deletion and revision after checking the proofreading sample on the personal interface of the system, please make a separate postscript to explain the revision in addition to the correction in the proofreading. After proofreading, please upload a scanned copy of the proofread manuscript co-signed by the first author and the corresponding author in the system to show your approval of the publication as such. In order to meet the needs of information construction and expand academic communication channels, the journal has joined important databases at home and abroad, and the one-time payment for each manuscript has included all manuscript fees such as digital publication. If the author does not agree with the inclusion of his manuscript in the database, please attach a letter to the submission and we will handle it appropriately. Once the manuscript is published, 3 copies of the current issue will be sent to the first author. For additional samples, please tell us the total number of samples required at the time of submission.

⑥ For manuscripts that are not suitable for publication, a rejection notice will be displayed on the personal interface of the author of the system in time. If an author abandons the submission in the middle of the process, he/she should notify the editorial office in the form of a written letter signed by all authors.

4 Contact information

Address: Editorial Office of Chinese Journal of Pharmacoepidemiology, Building 9, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuchang District, Wuhan, Hubei Province, China

Postal code: 430071

Email：service@ywlxbx.com

Tel: 027-67812505

Website: ywlxbx.whuznhmedj.com

Schedule (common medical research report specifications):

1.Randomized controlled trials and their derivative designs: CONSORT and its extension board (http://www.consort-statement.org/);

2.Observational studies and their derivative designs: STROBE and its extension board (http://www.strobe-statement.org);

3.Diagnostic/prognostic tests and their derivative designs: STARD and its extension board (www.stard-statement.org/);’

4.Case report: CARE (http://www.care-statement.org/);

5.Systematic review and Meta-analysis: PRISMA and its extension board (http://www.prisma-statement.org/);

6.Animal experiments: ARRIVE (http://www.nc3rs.org.uk/arrive-guidelines);

7.Clinical practice guidelines: RIGHT (http://www.right-statement.org/);

8.Research program: SPRIT (http://www.spirit-statement.org/);

9.Other medical reporting specifications for different types of studies are available on the EQUATOR (http://www.equator-network.org/) website.